WO2005035493A1 - アミノピロリジン誘導体の製造方法および中間体化合物 - Google Patents
アミノピロリジン誘導体の製造方法および中間体化合物 Download PDFInfo
- Publication number
- WO2005035493A1 WO2005035493A1 PCT/JP2004/015186 JP2004015186W WO2005035493A1 WO 2005035493 A1 WO2005035493 A1 WO 2005035493A1 JP 2004015186 W JP2004015186 W JP 2004015186W WO 2005035493 A1 WO2005035493 A1 WO 2005035493A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen atom
- production method
- amino
- halogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a method for producing an aminopyrrolidide conductor.
- infiltration of blood leukocyte components such as monocytes and lymphocytes into tissues plays a major role in the progression and maintenance of the disease.
- the present invention also relates to an anthranilamide amide n conductor which is a production intermediate useful for the synthesis of such an aminopyrrolidine derivative, and a method for producing the same.
- Chemokines such as MIP-1 ⁇ and MC ⁇ -1 are protein factors that have leukocyte migration-inducing and activating effects, and their effects are known to be expressed through chemokine receptors on leukocytes. Have (allergy's immunity, 199, Vol. 6, No. 11). Therefore, chemokine receptor ⁇ 3 ⁇ 43 ⁇ 4 ⁇ 3 ⁇ 4, which can inhibit the action of chemodynamics on target cells, is thought to play a major role in the progression and maintenance of disease due to infiltration of leukocytes into the arteriosclerosis.
- the chemokine receptor ⁇ an aminopyrrolidine having an action, a production method to obtain a conductor, the country!
- Examples of the preparation of compounds having a structure similar to that of the pamphlet No. 9/256/886 and the pamphlet of No. 9/5505334 are disclosed, but are disclosed therein.
- the production method is not simple, and the disclosed examples are not necessarily suitable for mass synthesis, such as using dichloromethane as the S solvent.
- many of these derivatives having a chemokine receptor activity have an antranilate amide skeleton as an example.Therefore, in order to obtain a wide range of compounds having a chemokine receptor activity, such a production intermediate is efficiently used. It had to be manufactured by a method suitable for mass synthesis.
- Examples of such compounds having a structure similar to anthraninoamide include Punfret No. 01 Z 053392 and International Publication No. 0/3 7141 No. 1 Pamfret 1, (this 2-pheninorea minobenzamide).
- a conductor is disclosed, but this compound has a hydroxamic acid structure, which is a glue sheet, and cannot be derived into the above-mentioned compound having a chemokine receptor effect.
- chemokine receptor P and a compound having an harmful effect
- a compound having an amide structure in a pamphlet is disclosed, as disclosed in International Publication No. 0/62/059, p.
- the compound having an anthranilic acid structure is not specifically disclosed, and therefore the production method is different. Disclosure of the invention
- An object of the present invention is to provide a simple and industrial process for producing a group of compounds described in International Patent Publication No. WO99 / 256686, which is a chemokine receptor antagonist.
- an object of the present invention is to provide a method capable of producing a target aminopyrrolidine derivative in a high yield under mild conditions while avoiding a halogen-based male having a high fiber load.
- the purpose of the present invention is to produce intermediates for the production of the compounds described in the pamphlet of Japanese Patent Application Laid-Open No. 9 / 956,686, particularly those intermediates suitable for producing the anthranilamide skeleton. It is to find out.
- Another object of the present invention is to provide a production method suitable for industrial production.
- the present inventors have studied for the above-mentioned purpose, and as a result, have found the production method of the present invention, an intermediate thereof and the production thereof; ig ⁇ method, and have reached the following invention. That is, the first invention is a method for producing an aminopyrrolidone conductor or a salt thereof, comprising Step 1 and Step S 2 represented by the following formula (I).
- R 1 and R 2 each independently represent a protecting group for a hydrogen atom or an amino group (in this case, R 1 and R 2 may be combined to form a ring structure),
- R 3 represents a hydrogen atom or a C-C 6 alkyl group
- R 2 represents a hydrogen atom, a C 6 anoalkyl group, or a C 2 -C 7 alkanoyl group (the carbon number includes a carbon atom);
- R 12 , R 14 , R] 5 , R 16 , and R 17 are each independently a hydrogen atom, a halogen atom, a C i -C 6 alkyl group which may be substituted with a halogen atom, and substituted with a halogen atom.
- Step 1 is unnecessary for # ⁇ in which R 1 and R 2 are also hydrogen atoms
- the present invention comprises only the reaction step 1 in the above formula. This is the method for producing the salt.
- the aminopyrrolidine derivative thus obtained may have optical isomers due to the presence of an asymmetric carbon on the pyrrolidine ring, but both the R-form and the S-form may be prepared by preparing a mixture thereof.
- the method is also included in the present invention. The same applies to the stereoisomers relating to the carbon atom to which R 3 is bonded in Table 1 where R 3 is an alkyl group.
- the second invention is A process for producing an aminopyrrolidine: derivative or a salt thereof, comprising a condensation step represented by ( ⁇ ).
- aminopyrrolidone conductor may be covered with an optical isomer due to the presence of carbon atoms on the pyrrolidine ring.
- both the method for producing the R-form and the S-form, and the method for producing a mixture thereof, are included in the present invention. included. The same applies to the stereoisomers for the carbon atom to which R 3 is attached in the table where R 3 is a C 6 alkyl group.
- a third invention is an anthranilamide amide derivative represented by the following formula (m) or a derivative thereof, which is an intermediate for producing the above aminopyrrolidide conductor.
- R 4 represents a hydrogen atom or a C 6 alkyl group.
- this compound may have a carboxyl group and a raw nitrogen, various salts can be formed, and such salts are also included in the present invention.
- a fourth invention is a method for producing the above anthranilic acid amide conductor or a salt thereof, comprising a ⁇ s step represented by the following fas ⁇ civ).
- R in Formula (IV), the definition of R 2, R 3, R 2 3, R 24, R 25, and R 26 are the same as in IWBR ⁇ (I). Also, the definition of R 4 is the same as that in formula ( ⁇ ).
- 1 3 (3 1 -. 6 and Table 1 ⁇ 3 ⁇ 4 a Arukiru group, but standing ⁇ body about the carbon atom to which R 3 is attached can be ⁇ , R body, any preparation of the S form BEST MODE FOR CARRYING OUT THE INVENTION
- the present invention includes both the method and the method for producing a mixture thereof.
- halogen atom refers to a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- R 1 and R 2 are respectively i insects elevational represents a hydrogen atom or a protective group for Amino group (this ⁇ , the super ⁇ become R 1 and R 2 gar cord May be formed).
- strong amino-protecting groups include methoxycarbonyl group, ⁇ -butoxycarbonyl group, benzyloxycarbonyl group, arinoleoxycanoleponinole group, honoleminole group, acetyl group, benzoinole group, methyl Groups, an ethyl group, an aryl group, a benzenesulfonyl group, and a phthalone group.
- the protecting group of the amino group has an aromatic ring, and the aromatic ring is one or more of a nitro group, an amino group, a C—C 6 alkyl group, a Ci—c 6 alkoxy group, or a halogen atom. It may be replaced.
- R 1 and R 2 preferably include a hydrogen atom, a butoxycarbonyl group, and a benzyloxycarbonyl group.
- R 3 represents a hydrogen atom or a C! —C 6 alkyl group.
- a hydrogen atom is preferable as a high force.
- R 4 represents a hydrogen atom or a C—Ce alkyl group. Hydrogen atoms and methyl groups are preferred as high power, and hydrogen atoms are particularly preferred.
- R 11 represents a hydrogen atom, a C—Cs alkyl group, or a C 2 -C 7 alkyl group.
- Power The mowing R 11, Shi preferred is hydrogen atom Les
- R 12 , R 14 , R 15 , R 16 , and R 17 are each; C —C which may be replaced by a hydrogen atom, a halogen atom, or a halogen atom 6 represents an alkyl group, a C 6 alkoxy group which may be substituted by a halogen atom, a hydroxy group, or a C 2 to C 7 alkoxy group.
- R 12 , R 14 , R 15 , and R 17 are preferably hydrogen atoms, and R 16 is C! A C 6 alkyl group, especially a methyl group, is preferred.
- R 23 , R 24 , R 25 , and R 26 are each independently a hydrogen atom, a halogen atom, a Ci—Ce alkyl group, and a halogen atom which may be substituted with a halogen atom.
- R 23 , R 24 , and R 26 are preferably hydrogen atoms, and R 25 is preferably a hydrogen atom, and R 25 is a C — C 6 alkoxy group substituted with a nitrogen atom, especially a trifluoromethoxy group. But preferred.
- the 3 ⁇ 4 & E step 1 in the ⁇ method represented by the ilBSJS formula (I) is a step of introducing an indole derivative into an aminopyrrolidine skeleton, and examples thereof include two main methods.
- a 3-position indole derivative in ⁇ -position RJ3 ⁇ 4 which binds the 3-position of the indole derivative to the primary or secondary amine through one methylene group, acts as a solvent with ethanol and acetic acid. It is preferable to use tetrahydrofuran at room temperature, and it is particularly preferable to use formaldehyde ⁇ 37% formalin as a facet.
- an indole derivative having a dialkylaminomethyl group at position 3 of indone may be ⁇ -substituted.
- the desired indole derivative can be obtained by allowing the indole derivative and the amine to react in an organic solvent.
- a solvent other than a ketone-based amine such as alcohols, aetheno, esters, and hydrocarbons is widely used. Among them, 2-propanol, propyl acetate, and toluene are preferable examples.
- Step 2 in the production method represented by the formula (I) is a step of deprotecting the amino group of the anthranil moiety, and is required only when the protecting group has been used.
- the raw material for obtaining the aminopyrrolidide conductor of the present invention can be produced, for example, by the following synthesis method.
- the definitions of RR 2 , R 3 , R 23 , R 24 , R 25 , and R 26 in the equation are as defined by tin. That is, an amino acid is condensed with an anthrani having an amino group at the 2-position, followed by bow I followed by condensation with benzylaminopyrrolidine.
- the raw material required for the present invention can be obtained by removing the benzyl group of the protecting group from the thus obtained aminopyrrolidone 1 conductor.
- the acquisition of the raw materials used in the production method of the present invention is not limited to the production route exemplified here.
- the production method exemplified here shows an outline of the synthetic zototo, and a step of using a pharmacotherapy can be added depending on the conditions of each compound.
- the definitions of R 3 , R ", R 12 , R 14 , R 15 , R 16 , R 17 , R 23 , R 24 , R 25 , and R 26 in the formula are as follows.
- 5 and R 6 each independently represent a hydrogen atom or an amino group-protecting group (R 5 and R 6 may be combined to form a ring structure), provided that R 5 and R 6 cannot be a hydrogen atom at the same time.
- Step 5 is a synthesis, which is carried out by reacting an anthranilic acid derivative with a condensing agent in an organic solvent.
- Kakaru examples include ⁇ , dimethinoleformamide, tetrahydrofuran, acetic esters, toluene, acetonitrile, dimethoxyethane, chloroform, dichloromethane, methanol, and 2-propanol.
- tetrahydrofuran, ⁇ , iV-dimethinoleformamide, ethyl acetate, 2-propanol, and methanol are preferred from the viewpoint of an industrial production method, and particularly, tetrahydrofuran, ethyl acetate, or 2-propanol-methanol and Is preferred.
- condensing agent examples include 1,3-dihexyl hexylcarbodiimide, isoptyl chloroformate, vivalic acid lip, isoyoshi kuguchi, and 1-ethyl-3- (3- Dimethylaminopropyl) carbodiimide, 1-cyclohexyl-1-31 morpholinoethyl carbodiimide, 1-cyclohexyl_ 3 _ (4-getylaminocyclohexyl) canolepoxyimide, 'N, AT monocarbonyl Examples include diimidazole, 2-chloro-1,3-dimethylimidazolidinamide, and isobutynole formate, among which 1-ethyl-3- (3-dimethinoleaminopropyl) carbodiimide, 11 Preferable is hexamorphyl hexyl-31-morpholinoethyl carboximid, and 1-cyclohexyl-1--3-
- an additive for promoting ⁇ & and improving the yield include p-nitrophenoleno, hydroxysuccinimide, hydroxyphthalenoimide, 1-hydroxy-1,2,3-benzotriazole, 3-hydroxy-4-oxo-3,4-dihydroxy-1,1,4-hydroxy-1,3 2,3- ⁇ -Nzotriazine, N-hydroxy-5-nonolepo / linen-2,3-dicanolevonic acid imide, and 2-hydroxyimino_2-cyanoacetic acid ethyl ester, among which hydroxysuccinimide ⁇ 1-hydroxy- 1,2,3-Benzotriazole is preferred.
- Such an auxiliary agent is usually required to be moved to 1.1. It is more preferable to use 0.1-0.2 equivalents of 1-hydroxy-1,2,3-benzotriazonole.
- Kagurashi salt Raw fillers include triethylamine and -methylmorpholine. In particular, Triethylamine is preferred.
- 1-ethyl-3- (3-dimethinoleaminopropyl) carbodiimide 3 ⁇ 4 ⁇ , 1-hydroxy-1,2,3-benzotriazole and triethylamine are used as a solvent with tetrahydrofuran or ethyl acetate as a solvent. It has the best operability and is particularly preferable.
- the starting material used in step (5) above is preferably produced in the same manner as in step S4 in the above formula.
- the protecting group for the amino group of R 5 there may be mentioned a methoxycarbonyl group, a butoxycarbol group, a benzyloxycarbol group, an aryloxycarbonyl group, a honoleminole group, an acetyl group, and a benzoyl group.
- the protecting group of the amino group has an aromatic ring, and the aromatic ring is one or more of a nitro group, an amino group, a C—C 6 alkanol group, a ⁇ —C 6 anorecoxy group, or a nodogen. It may be substituted by an atom.
- R 5 and R 6 are preferably a hydrogen atom and a t-butoxycarbonyl group.
- the fourth step is to deprotect the amino group.
- a 1-butoxycarpoxyl group as a protecting group for the amino group
- m hydrogen chloride, getyler terephthalate, hydrogen chloride / 1,4-dioxane intensely, salt B.
- Chlorinated water such as K / methanol descendant, etc. It can be removed by adding acid such as tasin or trifluoroacetic acid. ⁇ ⁇ ⁇ ⁇ using hydrogen chloride / 1,4 dioxane descendants or chlorine / methanol windows is particularly preferred.
- the starting material used in the above SiSCL 4 is preferably produced as in step 3 in the above formula (1).
- Powerful Step 3 is the introduction of indole (a conductor) into the aminopyrrolidine skeleton. This step is similar to the <> step 1 in the first invention, and there are roughly two methods as examples. One is a method in which 11 formaldehydes such as phono-phosphorus, paraformano'hid, tri'oxane, etc. are allowed to react with an indole derivative in which the 3-position is exchangeable.
- 11 formaldehydes such as phono-phosphorus, paraformano'hid, tri'oxane, etc.
- a solvent such as acetic acid / 1,4-dioxane mixture (mixing ratio is, for example, 1: 1), ethanol, methanol, acetic acid / methanol (mixing ratio is arbitrary)
- the third position of indole derivative, The primary or secondary amine is linked through one methylene group. fi ⁇ u It is preferable to use ethanol as a solvent at room temperature, and to use 37% phono! ⁇ Phosphorus is particularly preferred.
- an indole derivative having a dialkylaminomethyl group at the 3-position may be used. That is, by subjecting the indole derivative and the amine to ⁇ S in a solvent, the desired indole rust conductor can be obtained.
- the solvent it is preferable to use an alcohol or an organic solvent having a boiling point of 70 to 120 ° C., particularly, 2-propano.
- the obtained product can form a salt such as a mono salt for purification.
- the starting material used in the above IB®S step 3 is preferably produced as in step 2 in the Kamiso formula. .
- Step 2 is ⁇ & which removes the benzyl group reductively.
- Such examples include palladium on carbon, 7_k palladium (II) oxide, palladium on carbon, etc., in alcoholic solvents such as methanol, ethanol, 2-propanol, hydrogen gas, formic acid, or ammonium formate.
- hydrogen gas As a hydrogen source.
- the starting material used in step 2 of gi3 ⁇ 4 is preferably produced as in step 1 in the above formula.
- Step 1 is also the same condensation as in step 5, and proceeds by using a condensing agent in a shelf solvent and reacting the amino group-protected amino acid.
- the conditions are the same as those described in Reaction 5.
- the aminopyrrolidone conductor as the final product in the second invention and the intermediate for producing the same have assimilar nitrogen and can be converted into a salt.
- Such salts include, for example, salts of sulfuric acid, acetic acid, phosphoric acid, and citric acid, among which salts of sulfuric acid and acetic acid are particularly preferred.
- the final product the aminopyrrolidone conductor
- the aminopyrrolidone conductor has an asymmetric carbon, and the power that the photoreceptor can provide. According to the production method of the present invention, it is possible to produce the compound essentially without both isomers. You. It is also possible to produce a mixture of both living organisms. Next, a third invention and a fourth invention will be described.
- R 2 3, R 24, R 25, and R 2 6 are respectively;
- M insects elevational a hydrogen atom, a halogen atom, Bruno , Replaced by a logen atom Represents a C j -C 6 alkyl group, a mono-C 6 alkoxy group which may be formed by a hydrogen atom or a halogen atom, or a hydroxy group.
- L is preferably a hydrogen atom.
- R 25 is preferably a C—C 6 alkoxy group substituted with a halogen atom, and particularly preferably a trifluoromethoxy group.
- this compound has raw nitrogen and may have a carboxyl group, it is possible to form any of an acid and a ⁇ -salt as far as chemically possible.
- the production method of the present invention is the same as that of ttffS, but it is preferable to carry out the following steps.
- the definitions of RR 2 , R 3 , R 4 , R 23 , R 24 , R 25 , and R 26 in the formula are as per lilt.
- reaction step 1 is a step of introducing a protecting group into the amino group portion of anthralic acid.
- a strong protecting group a group such as a t-butoxycarbol group or a benzyloxycarbol group, which forms a carpalmate with the amino group, is preferred.
- R 1 and R 2 Other specific examples have been given above as preferred groups for R 1 and R 2 .
- (B oc) 20 or Z—C 1 or the like acts on the amino group.
- ⁇ -dimethylformamide ⁇ tetrahydrofuran, acetates and the like are used.
- it is desirable to add a tertiary amine such as triethylamine or pyridin to accelerate SJ3 ⁇ 4. However, it will proceed without these additions.
- the target amides can be produced by performing the following SJS on such protection at ⁇ 3 ⁇ 4 ⁇ , but there is a problem that by-products of the condensed ring are formed by the hydrolysis in the step 3.
- Step 2 is a flH synthesis step in which a condensing agent is added in a solvent on a shelf, and a carboxyl group-protected amino acid or a salt thereof is allowed to act.
- N V-dimethylformamide, tetrahydrofuran, ethyl ethyl ester, tonoleene, acetonitrile, dimethyloxetane, chlorophonolem, dichloromethane, methanol, or 2-propanol
- tetrahydrofuran, N, -dimethinoleformamide, estenoacetate, methanolone, and (2) are preferably 2-propanol, particularly tetrahydrofuran or ethyl acetate.
- condensing agent examples include 1,3-dihexyl hexylcarbodiimide, isobutynolechloroformate, vivalic acid lip, isoyoshi kuguchi, 1-ethyl 3- (3- Dimethylaminopropyl) Ruposimide or its: M, 1-hexoxyl hexyl 3-morpholinoethyl carbodiimide, 1-six-hexyl hexyl 3-, 4- (4-ethylethylaminohexyl) carboxy.
- 1-ethyl-31- (3-dimethinoleaminopropinole) carbodiimide, 1-hexyl hexyl 3-morpholinoethyl carbodiimide, and 1-cyclohexyl hexyl 3- (4-ethylpyramino) canolepoxyimide are preferred.
- 1-ethynole-3- (3-dimethylaminopropyl) carbopimid salt is particularly preferred.
- additives include p-nitrophenol, hydroxysuccinimide, hydroxyphthalenoimide, 1-hydroxy-1,2,3-benzotriazole, and 3-hydroxy-4-oxo.
- 3-hydroxy-4-oxo 3-hydroxy-4-oxo.
- hydroxysuccinic acid imide ⁇ 1-hydroxy-1,2,3-benzotriazole is preferred.
- These additives are usually 0.1 to 1.0 ft *. More preferably, 0.1-0.2 equivalents of 1-hydroxy-1,2,3-benzotriazolone are used.
- the amines used in the amides are « ⁇ : ⁇ is to remove ⁇ -forming chlorine and to promote ⁇ ; it is preferable to add a sex additive. This can be used together with the above additives.
- the bulking agent include triethylamine and —methyl & ruphorin. In particular, Triethylamine is preferred.
- Step 3 of the SJII is a conservative step in which the protecting group for the amino-acid lipoxyl group is deprotected.
- esters are preferable, and methyl esters are particularly preferable.
- Both ⁇ S are made under general conditions as caro water early ⁇ 3 ⁇ 4.
- the audible was separated with 2 M 12 OmL, 240 mL of ethanol was added to the aqueous layer, and the mixture was homogenized overnight. The mixture was neutralized with 12 OmL of 2 M sodium hydroxide. The resulting insolubles were separated by filtration and enjoyed to obtain 1.70 g of the title compound.
- the precipitated crystals were collected by filtration and dried to give the title compound.
- the ft ⁇ product obtained here was dissolved in 160 mL of methanol, and the mixture was recrystallized by adding 160 mL of 2-propanol to obtain 41.01 g of the title compound.
- the aqueous layer was extracted with 20 OmL of ethyl acetate. ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ 1 1 1 1 1 1 1 1 1 1 1 ⁇ 1 1 ⁇ 1 ⁇ 1 ⁇ ⁇ 1 ⁇ ⁇ ⁇ , ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ .
- the desiccant was filtered off. The filtrate was concentrated to give a concentrate, which was purified to give 17.06 g of the title compound.
- anthranilic acid Kfl conductor of the present invention when used as a production intermediate, a large aminopyrrolidine; conductor can be easily produced.
- the production method that goes through this conversion ⁇ ) is satisfactory as an industrial production method in terms of equipment, operation, and the like.
- a large anthranilate amino acid conductor itself can be easily produced.
- the anthranilate amine of the present invention is used as an intermediate for producing a pharmaceutical, and the aminopyrrolidone conductor obtained by the production method of the present invention is used as a pharmaceutical.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004279721A AU2004279721A1 (en) | 2003-10-08 | 2004-10-07 | Process for producing aminopyrrolidine derivative and intermediate compound |
EP04792414A EP1676837A4 (en) | 2003-10-08 | 2004-10-07 | METHOD FOR PRODUCING AN AMINOPYRROLIDINE DERIVATIVE AND AN INTERMEDIATE COMPOUND |
US10/574,688 US20070073064A1 (en) | 2003-10-08 | 2004-10-07 | Method for producing aminopyrrolidine derivatives and intermediate compounds |
CA002542012A CA2542012A1 (en) | 2003-10-08 | 2004-10-07 | A method for producing aminopyrrolidine derivatives and intermediate compounds |
BRPI0415018-0A BRPI0415018A (pt) | 2003-10-08 | 2004-10-07 | métodos para a produção de derivados de aminopirrolidina e de antranilamida, e, composto |
JP2005514653A JPWO2005035493A1 (ja) | 2003-10-08 | 2004-10-07 | アミノピロリジン誘導体の製造方法および中間体化合物 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-349318 | 2003-10-08 | ||
JP2003349318 | 2003-10-08 | ||
JP2003350441 | 2003-10-09 | ||
JP2003-350441 | 2003-10-09 | ||
JP2003350439 | 2003-10-09 | ||
JP2003-350439 | 2003-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005035493A1 true WO2005035493A1 (ja) | 2005-04-21 |
Family
ID=34437593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015186 WO2005035493A1 (ja) | 2003-10-08 | 2004-10-07 | アミノピロリジン誘導体の製造方法および中間体化合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070073064A1 (ja) |
EP (1) | EP1676837A4 (ja) |
JP (1) | JPWO2005035493A1 (ja) |
AU (1) | AU2004279721A1 (ja) |
BR (1) | BRPI0415018A (ja) |
CA (1) | CA2542012A1 (ja) |
TW (1) | TW200517363A (ja) |
WO (1) | WO2005035493A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006109836A1 (en) * | 2005-04-07 | 2006-10-19 | Teijin Pharma Limited | Crystal of aminopyrrolidine derivative and prodcution method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001523661A (ja) * | 1997-11-18 | 2001-11-27 | 帝人株式会社 | 環状アミン誘導体、およびその薬剤としての使用法 |
WO2002050019A2 (en) * | 2000-12-20 | 2002-06-27 | Bristol-Myers Squibb Pharma Co. | Diamines as modulators of chemokine receptor activity |
WO2002060859A2 (en) * | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
JP2002532570A (ja) * | 1998-12-22 | 2002-10-02 | ワーナー−ランバート・カンパニー | 併用化学療法 |
JP2003504400A (ja) * | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた慢性痛の治療方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851418A (en) * | 1987-08-21 | 1989-07-25 | Warner-Lambert Company | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent |
US5177217A (en) * | 1992-04-27 | 1993-01-05 | Warner-Lambert Company | Process for the manufacture of (S)-3-amino-1-substituted-pyrrolidines |
CN1208318C (zh) * | 1999-12-08 | 2005-06-29 | 帝人株式会社 | 环胺ccr5受体拮抗剂 |
EP1483241A4 (en) * | 2002-03-08 | 2006-12-13 | Bristol Myers Squibb Co | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
-
2004
- 2004-10-07 AU AU2004279721A patent/AU2004279721A1/en not_active Abandoned
- 2004-10-07 BR BRPI0415018-0A patent/BRPI0415018A/pt not_active IP Right Cessation
- 2004-10-07 JP JP2005514653A patent/JPWO2005035493A1/ja not_active Withdrawn
- 2004-10-07 EP EP04792414A patent/EP1676837A4/en not_active Withdrawn
- 2004-10-07 US US10/574,688 patent/US20070073064A1/en not_active Abandoned
- 2004-10-07 WO PCT/JP2004/015186 patent/WO2005035493A1/ja active Application Filing
- 2004-10-07 CA CA002542012A patent/CA2542012A1/en not_active Abandoned
- 2004-10-08 TW TW093130663A patent/TW200517363A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001523661A (ja) * | 1997-11-18 | 2001-11-27 | 帝人株式会社 | 環状アミン誘導体、およびその薬剤としての使用法 |
JP2002532570A (ja) * | 1998-12-22 | 2002-10-02 | ワーナー−ランバート・カンパニー | 併用化学療法 |
JP2003504400A (ja) * | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた慢性痛の治療方法 |
WO2002050019A2 (en) * | 2000-12-20 | 2002-06-27 | Bristol-Myers Squibb Pharma Co. | Diamines as modulators of chemokine receptor activity |
WO2002060859A2 (en) * | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006109836A1 (en) * | 2005-04-07 | 2006-10-19 | Teijin Pharma Limited | Crystal of aminopyrrolidine derivative and prodcution method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20070073064A1 (en) | 2007-03-29 |
EP1676837A4 (en) | 2008-09-10 |
CA2542012A1 (en) | 2005-04-21 |
EP1676837A1 (en) | 2006-07-05 |
BRPI0415018A (pt) | 2006-11-28 |
AU2004279721A1 (en) | 2005-04-21 |
JPWO2005035493A1 (ja) | 2006-12-21 |
TW200517363A (en) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991008195A1 (en) | N-(1-(2-carboxyethyl)cycloalkyl carbonyl)-beta-alanine derivatives for pharmaceutical use | |
WO2017108960A1 (en) | Method for producing monomethyl fumarate compounds | |
JP3488155B2 (ja) | 成長ホルモン分泌促進物質の製造及び中間体 | |
JP7136527B2 (ja) | 3-[(3s)-7-ブロモ-2-オキソ-5-(ピリジン-2-イル)-2,3-ジヒドロ-1h-[1,4]-ベンゾジアゼピン-3-イル]プロピオン酸メチルエステルの調製方法及びその方法に有用な化合物 | |
US20240109841A1 (en) | Compositions of trofinetide | |
KR20190044652A (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
WO2005035493A1 (ja) | アミノピロリジン誘導体の製造方法および中間体化合物 | |
EA014874B1 (ru) | Соединения для ингибирования апоптоза | |
JP2007513863A (ja) | 新規化合物 | |
WO1991010644A1 (en) | Cycloalkyl-substituted glutaramide diuretic agents | |
TW482763B (en) | 1,3,4-oxadiazole derivatives and a process for preparing the same | |
TW202235078A (zh) | 自分泌運動因子(autotaxin)之新穎的抑制劑 | |
JP2004504405A (ja) | 化学的方法 | |
JP2007023029A (ja) | 医薬組成物 | |
JP7430297B2 (ja) | N-アルキルアミノ酸、およびn-アルキルアミノ酸を含むペプチドの製造方法 | |
CN119119058A (zh) | 一种乌帕替尼的合成方法、其中间体及其中间体的制备方法 | |
WO1998049186A1 (en) | Dipeptide surrogates containing asparagine-derived tetrahydropyrimidinones | |
JP2853020B2 (ja) | グアニジン誘導体及びその製造方法 | |
TW202432123A (zh) | 作為il—17調節劑之咪唑并三𠯤衍生物 | |
JP2005112787A (ja) | アミノピロリジン誘導体の製造法 | |
JPH083162A (ja) | イミダゾピリジン誘導体及びその製法 | |
JP4246948B2 (ja) | 光学活性ピロリドン誘導体の製造法 | |
JP2005112803A (ja) | アセトアミドピロリジン誘導体の製造法 | |
JPH0645583B2 (ja) | シクロアルキル置換グルタルアミド系利尿薬 | |
JP2006528168A (ja) | インテグリン阻害剤として有用な、rgd配列を含有するペプチド様化合物及びその中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480029562.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514653 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1776/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004279721 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007073064 Country of ref document: US Ref document number: 10574688 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067006770 Country of ref document: KR Ref document number: 2542012 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004792414 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004279721 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004792414 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0415018 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067006770 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10574688 Country of ref document: US |